MedTrace Logo

Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

NCT05897528 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 589

Last updated 2023-06-09

No results posted yet for this study

Summary

The Coronavirus Disease of 2019 (COVID-19) pandemic has caused an international healthcare crisis and produced a large healthcare burden. Diabetes mellitus is a common disease that can be controlled via pharmacologic agents; however, many patients have poor glycemic control, leading to disease-related complications. Diabetes mellitus has been reported in the literature to be associated with increasing morbidity and mortality in COVID-19 patients, and some hypothesize that this is due to insulin dysregulation propagating a pro-inflammatory state. The investigators aim to contribute to the growing body of literature that assesses the associations between glucose homeostasis and COVID-19 disease severity and mortality.

Conditions

Interventions

OTHER

No Intervention

Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups

Sponsors & Collaborators

  • Arrowhead Regional Medical Center

    lead OTHER

Principal Investigators

  • Alexander Phan, MD · Arrowhead Regional Medical Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-14
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05897528 on ClinicalTrials.gov